Relationship between natural killer (NK) cell activity and erbB-2 expression in colorectal cancer patients

Periodicum Biologorum

Volumn 100, Issue 4, 1998, Pages 537-539

  Lukač, Josip ^a   Kovačević, Dujo ^a   Krušlin, Božo ^a   Spaventi, Radan ^b   Ferenčić, Željko ^b   Belicza, Mladen ^a   Desyo, Drago ^a   Kusić, Zvonko ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b PLIVA CROATIA LTD   (Croatia)

Author keywords

Colorectal cancer; erbB 2; NK cell activity

Indexed keywords

ALKALINE PHOSPHATASE;

ADULT; AGED; ARTICLE; CELL STRAIN K 562; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NATURAL KILLER CELL; ONCOGENE NEU;

EID: 0032422109     PISSN: 00315362     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. KOSCIELNY S, TERIER P H, DAVER A, WAFFLART J, GOUSSARD J, RICOLLEAU G, DELVINCOURT C, DELARUE J C 1998 Quantitative determination of c-erbB-2 in human breast tumors: potential prognostic significance of low values. Eur J Cancer 34: 476-481
2. KAPITANOVIĆ S. RADOŠEVIĆ S, KAPITANOVIĆ M, ANDELINOVIĆ S, FERENČIĆ Ž, TAVASSOLI M, PRIMORAC D. SONICH Z, SPAVENTI Š, PAVELIĆ K, SPAVENTI R 1997 The expression of p185HER-2/neu correlates with the stage of the disease and survival in colorectal cancer. Gastroenterology 112: 1103-1113
3. BRODOWICZ T, ZILLINGER R, WITSCHKE C, SCHOLTEN C, SEIFERT M, KUBISTA E, ZIELINSKI C C 1997 Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology 54: 475-481.
4. JASS J R 1986 Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol 239: 585-589
5. HERBERMAN R B 1992 Tumor immunology. JAMA 268: 2935-2939
6. BAIER P K, WIMMENAUER S, HIRSCH T, V SPECHT B U, V KLEIST S, KELLER H, FARTHMANN E H 1998 Analysis of the T cell receptor variability of tumor-infiltrating lymphocytes in colorecial carcinomas. Tumor Biol 19: 205-212
7. LUKAČ J, KOVAČEVIĆ D, KORDIĆ D. LADIKA B, TROSKOT B, KAPITANOVIĆ S, FERENČIĆ Ž. SPAVENTI R, KUSIĆ Z 1997 Soluble erbB-2 oncoprotein in colorectal cancer patients. Tumor Biol 18: 122
8. LUKAČ J, KUSIĆ Z, KORDIĆ D, KONČAR M, BOLANČA A 1994 Natural killer cell activity, phagocytosis, and number of peripheral blood cells in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 29: 279-285.
9. RAVDIN P M, CHAMNESS G C 1995 The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review. Gene 159: 19-27
10. HANNA N, BURTON R C 1986 Definitive evidence that natural killer cells inhibit experimental tumor metastasis in vivo. J Immunol 127: 1754-1758
11. LICHTENSTEIN A, BERENSON J, GERA J F, WALDBURGER K, MARTINEZ-MAZA O, BEREK J S 1990 Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes. Cancer Res 50: 7364-7370
12. WILTSCHKE C, SPEISER P, STEININGER A, ZEILLINGER R, KURY F, KUBISTA E, PREIS P, KRAINER M, ZIELINSKI C 1994 Increased natural killer cell activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer. Cancer 73: 135-139